Genomic and Proteomic Profiling of Childhood AML
N/A
20 Years
Both
Leukemia
Trial Information
Genomic and Proteomic Profiling of Childhood AML
OBJECTIVES:
- To profile basal and potentiated phospho-protein networks (PPPNs) using tissue samples
from pediatric patients with de novo acute myeloid leukemia (AML) previously enrolled
on clinical trial POG-9421.
- To classify AML-based signal transduction mechanisms.
- To correlate profiles of basal and PPPNs with specific molecular lesions (e.g.,
FLT3-ITD, NPM, WT1, c-kit, CEPBα, PASGΔ75, and karyotype) and profiles of gene
expression in tumor tissue samples.
OUTLINE: Banked tissue samples are collected for laboratory studies, including
phospho-protein signaling and gene expression profiling studies.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of acute myeloid leukemia, meeting 1 of the following criteria:
- Primary induction failure (i.e., failed to achieve remission within the first 60
days of therapy)
- Relapsed disease (early or late)
- In continuous complete remission
- Previously enrolled on POG-9421
- Tissue samples available
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Profiling of basal and potentiated phospho-protein networks (PPPNs) using tissue samples
Safety Issue:
No
Principal Investigator
Norman J. Lacayo, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
United States: Federal Government
Study ID:
CDR0000659560
NCT ID:
NCT01035307
Start Date:
October 2009
Completion Date:
Related Keywords:
- Leukemia
- childhood acute myeloid leukemia in remission
- recurrent childhood acute myeloid leukemia
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
Name | Location |
|---|
